

2739-7369

Oral Antidiabetics

Contributors

H.J. Ahr, S.L. Ali, J.M. Amatruda, E.M. Bardolph, H. Bischoff,
H.H. Blume, E.-M. Bomhard, E. Brendel, L. Groop, F. Hartig,
A. Hasselblatt, L.S. Hermann, B. Junge, J. Köbberling,
H.P. Krause, J. Kuhlmann, K.H. Langer, H.E. Lebovitz,
P.J. Lefèbvre, M. Matzke, M.L. McCaleb, G. Neugebauer, M. Noel,
P. Ochlich, U. Panten, H.J. Ploschke, H. Plümpe, E. Prugnard,
W. Puls, W. Rebel, A.J. Scheen, H. Schlecker, F.H. Schmidt,
B.S. Schug, E. Schütz, C. Schwanstecher, M. Schwanstecher,
S. Seip, J. Stoltefuss, R.H. Taylor, N.F. Wiernsperger,
W. Wingender, C. Wünsche

Editors

Jochen Kuhlmann and Walter Puls



Springer

25-

Contents

CHAPTER 1

Introduction

J. KUHLMANN	1
References	5

CHAPTER 2

Pathophysiology of Type 2 Diabetes Mellitus

A.J. SCHEEN and P.J. LEFÈBVRE. With 5 Figures	7
A. Introduction	7
I. Heterogeneous Disease	7
II. Genetic Background	8
III. Environmental Factors	8
B. Abnormalities of the Glucose-Insulin Feedback Loop	9
I. Insulin Secretion	10
1. How to Measure Insulin Secretion?	11
2. Abnormal Plasma Concentrations	12
3. Abnormal Kinetics Response	13
4. Varia	14
II. Insulin Sensitivity	14
1. Hepatic Glucose Production	14
2. Splanchnic Glucose Uptake	16
3. Peripheral (Muscle) Glucose Uptake	16
4. Adipose Tissue Lipolysis	18
5. Increased Glucagon Secretion	19
6. Varia	19
C. Possible Causal Defects	19
I. Insulin Secretion	19
1. B-Cell Number	19
2. Insulin Gene	20
3. Amylin	21
4. GLUT 2	21
5. Glucokinase	21

6. Accumulation of B-Cell Glycogen	22
7. Varia	22
II. Insulin Sensitivity	23
1. Insulin Pre-receptor Level	23
2. Insulin Receptor Level	24
3. Insulin Post-receptor Level	25
4. Varia	28
D. Role of Associated Obesity	29
I. Impact of Obesity on Insulin Secretion	29
II. Impact of Obesity on Insulin Sensitivity	29
III. Lipid Oxidation and Insulin Resistance	30
IV. From Obesity to Type 2 Diabetes	30
E. Dynamic Interaction Between Insulin Action and Insulin Secretion	31
I. What Is the Primary Defect?	31
II. Transient Compensatory Mechanisms	32
III. Role of Glucose Toxicity	33
IV. Vicious Circle Leading to Severe Hyperglycaemia	33
F. Conclusions	34
References	35

CHAPTER 3

Non-Pharmacological Management of Non-Insulin-Dependent Diabetes

J. KÖBBERLING	43
A. Dietary Management	43
I. General Basis for Recommendations	43
II. Total Energy Intake	44
1. Overweight NIDDM Patients	44
2. Normal Weight NIDDM Patients	45
III. Carbohydrates	46
1. Dietary Fibres	46
2. Simple Sugars	48
3. Glycaemic Index of Various Carbohydrates	48
IV. Dietary Fat	49
V. Dietary Protein	50
VI. Other Dietary Factors	51
1. Sodium	51
2. Alcohol	51
3. Vitamins, Minerals and Trace Elements	51
VII. Dietary Specialities for Diabetics	52
1. Sweeteners	52
2. Diabetic Foods	52

VIII. Problems and Techniques of Dietary Advice	52
IX. Dietary Recommendations in "Non-Western" Societies ...	53
1. India and Southeast Asia	53
2. Japan	54
3. China	55
4. Africa	55
B. Exercise	55
I. Insulin-Dependent Diabetes	56
II. Non-Insulin-Dependent Diabetes	56
1. Short-Term Effects	56
2. Long-Term Effects	57
III. Recommendations	58
References	59

Section I: Sulfonylureas

CHAPTER 4

Sulfonylureas and Related Compounds:

Chemistry and Structure-Activity Relationships

H. PLÜMPE. With 1 Figure	65
A. Introduction	65
B. Sulfonylureas	66
I. Variation of R^1	66
II. Variation of R^2	69
C. Sulfonylsemicarbazides	69
D. Sulfonylaminopyrimidines	69
E. Various Nonmarketed Compounds of Interest	69
F. Conclusions	71
References	71

CHAPTER 5

Sulfonylureas: Physicochemical Properties, Analytical Methods of Determination and Bioavailability

S.L. ALI, H.H. BLUME, and B.S. SCHUG. With 15 Figures	73
A. Introduction	73
B. Physical Properties	73
I. Description	73
II. Melting Point	73

III. Solubility	73
1. Acetohexamide	76
2. Acetylcarbutamide	76
3. Carbutamide	77
4. Chlorpropamide	77
5. Glibenclamide	77
6. Glimepiride	77
7. Glipizide	77
8. Gliquidone	77
9. Glisoxepide	77
10. Metahexamide	78
11. Tolazamide	78
12. Tolbutamide	78
IV. Dissociation Constants	79
V. Crystal Shape and Structure	79
1. Acetohexamide	79
2. Glimepiride	80
3. Tolbutamide	80
C. Ultraviolet Spectrum	82
D. Infrared Spectrum	82
E. Nuclear Magnetic Resonance Spectrum	86
F. Mass Spectrum	86
G. Color and Identification Reactions	88
I. Acetohexamide, Glibornuride, Gliquidone	91
II. Carbutamide	91
III. Chlorpropamide	91
IV. Glibenclamide	91
V. Tolbutamide	91
H. Stability and Degradation	92
I. Acetohexamide	92
II. Chlorpropamide	92
III. Glibenclamide	92
IV. Glimpiride	93
V. Glisoxepide	93
VI. Tolbutamide	93
I. Methods of Analysis	94
I. Titrimetry	94
1. Acetohexamide	94
2. Carbutamide	94
3. Chlorpropamide	95
4. Glibenclamide	95
5. Glipizide	95
6. Glisoxepide	95
7. Tolazamide	95
8. Tolbutamide	95

II. Ultraviolet Spectrophotometry	96
1. Acetohexamide	96
2. Carbutamide	96
3. Chlorpropamide	96
4. Glibenclamide	96
5. Glipizide	96
6. Tolbutamide	97
III. Colorimetric Methods	97
1. Carbutamide	97
2. Glibenclamide	97
3. Tolbutamide	98
IV. Fluorimetry	98
V. Miscellaneous Methods	98
J. Chromatographic Methods	98
I. Paper Chromatography	99
II. Thin-Layer Chromatography	99
III. Gas-Liquid Chromatography and Mass Spectrometry	99
1. Acetohexamide	99
2. Chlorpropamide	99
3. Glibenclamide	103
4. Tolazamide	103
5. Tolbutamide	103
IV. High-Performance Liquid Chromatography	104
1. Acetohexamide, Chlorpropamide, Glibornuride, Gliclazide, Tolazamide	104
2. Carbutamide	106
3. Glibenclamide, Glipizide	106
4. Glimepiride	107
5. Glisoxepide	108
6. Tolbutamide	108
K. Bioavailability	108
1. Acetohexamide	111
2. Chlorpropamide	111
3. Glibenclamide (Glyburide)	113
4. Gliclazide	115
5. Glimepiride	117
6. Glipizide	117
7. Gliquidone	118
8. Glisoxepide	119
9. Tolazamide	119
10. Tolbutamide	119
References	121

CHAPTER 6

Mode of Action of Sulfonylureas

U. PANTEN, M. SCHWANSTECHEER, and C. SCHWANSTECHEER.

With 3 Figures	129
A. Introduction	129
B. Actions on Pancreatic β Cells	130
I. Stimulation of Insulin Secretion	130
II. Inhibition of the K_{ATP} Channel	131
III. Location of the Sulfonylurea Receptor	134
IV. Properties of the Binding Sites for Sulfonylureas	135
V. Structure of Compounds Interacting with the Sulfonylurea Receptor	140
C. Actions on Non- β Cells in Pancreatic Islets	143
D. Actions on Neurons	144
E. Actions on Cardiac Cells	145
F. Actions on Smooth Muscle	147
G. Actions on Skeletal Muscle	147
H. Actions on Miscellaneous Cells	148
I. Conclusions	148
References	149

CHAPTER 7

Sulfonylureas: Pharmacokinetics in Animal Experiments

A. HASSELBLATT	161
A. Introduction	161
B. Absorption of Sulfonylurea Derivatives After Oral Administration	162
I. Species Differences in the Rate of Absorption	162
II. Kinetics of Absorption of Sulfonylureas and Effects of Food and Other Drugs	163
III. Dependence of Absorption on Galenic Formulation	164
C. Distribution of Sulfonylurea Derivatives in the Organism	164
I. Space of Distribution of Sulfonylurea Derivatives	164
II. Protein Binding of Sulfonylureas and Interaction with Other Compounds on Plasma Protein-Binding Sites ..	167
D. Accumulation of Sulfonylurea Derivatives in Different Organ Systems	169
I. Accumulation in the Liver	169
II. Accumulation of Sulfonylurea Derivatives in the Pancreatic Islets	169
E. Elimination of Sulfonylurea Derivatives	171

F. Influence of Other Drugs on Rate of Metabolism and Excretion of Sulfonylurea Drugs	175
G. Possible Implications of the Results from Animal Experiments on the Pharmacokinetics of Sulfonylurea Derivatives for Clinical Applications in Humans	176
References	178

CHAPTER 8

Toxicology of Sulfonylureas

F. HARTIG, K.H. LANGER, W. REBEL, F.H. SCHMIDT, and E. SCHÜTZ	185
A. Introduction	185
B. Acute Toxicity	185
C. Chronic Toxicity	187
I. Carbutamide	187
1. Rats	187
2. Dogs	187
II. Tolbutamide	187
III. Chlorpropamide	188
1. Rats and Mice	188
2. Dogs	188
IV. Acetohexamide	189
V. Tolazamide	189
VI. Glibenclamide	189
VII. Gliclazide	189
VIII. Glipizide	190
IX. Gliquidone	190
X. Glibornuride	190
XI. Glisoxepide	190
1. Subchronic and Chronic Toxicity in Rats	190
2. Chronic Toxicity in Dogs	191
D. Reproduction Toxicology	191
I. Glibenclamide	191
II. Glisoxepide	192
III. Gliquidone	192
IV. Glibornuride	192
E. Mutagenicity	192
F. Other Toxicological Studies	193
I. In Vivo Studies	193
II. In Vitro Studies	194
G. Conclusions	196
References	196

CHAPTER 9

Clinical Pharmacology of Sulfonylureas

L. GROOP and G. NEUGEBAUER. With 3 Figures	199
A. Pharmacodynamics	199
I. Mode of Action of Sulfonylureas	199
1. Effects on Insulin Secretion	199
II. Hepatic Insulin Clearance	203
III. Other Pancreatic Effects	203
IV. Extrapancreatic Effects	204
V. Combination of Insulin and Sulfonylurea	205
VI. Rational Use of Sulfonylurea Drugs	206
B. Pharmacokinetics	207
I. Similarities and Differences	207
II. Timing of Drug Intake	208
III. Effect of Hyperglycemia	211
IV. Dose- and Concentration-Response Relationship	211
1. First-Phase Insulin Secretion	212
2. Second-Phase Insulin Secretion	213
3. Fasting Blood Glucose	213
4. Postprandial Blood Glucose	214
5. Euglycemic and Hyperglycemic Clamp	215
V. Specific Pharmacokinetics	216
1. Chlorpropamide	216
2. Glibenclamide	218
3. Gliclazide	221
4. Glipizide	223
5. Tolbutamide	225
6. Tolazamide	227
7. Glibornuride	228
8. Gliquidone	229
9. Acetohexamide	231
10. Glisoxepide	232
11. Glyclopamide	232
12. Glymidine Sodium	232
13. Carbutamide	233
14. Glipentide	234
15. Drugs Under Clinical Investigation	234
C. Safety and Tolerance	235
I. Hypoglycemia	235
II. Sulfonylurea Failure	235
III. Other Adverse Effects	236
IV. Interactions	237
References	237

Section II: Biguanides**CHAPTER 10****Chemistry and Structure-Activity Relationships of Biguanides**

E. PRUGNARD and M. NOEL	263
A. Introduction	263
I. The First Known Synthesis	263
II. The Golden Age	264
III. Nomenclature	264
IV. New Antihyperglycemic Biguanides	266
B. Chemistry	267
I. Synthesis	267
1. Unsubstituted Biguanides	269
2. N-Monosubstituted and N,N-Disubstituted Biguanides	269
3. N,N'-Substituted Biguanides	270
4. N,N''-Substituted Biguanides	270
5. N,N',N'',N'''-Substituted Biguanides	271
II. Stability Degradation	272
1. Thermal Decomposition	272
2. Action of Mineral Acids	272
3. Action of Alkalis	273
4. Action of Reducing Agents	273
5. Action of Oxidizing Agents	273
III. Cyclization Reactions	274
1. Cyclization with Derivatives of Carboxylic Acids	274
2. Cyclization with Carbonyl Compounds	274
3. Cyclization with β -Difunctional Compounds	275
4. Cyclization with Benzil or Benzoin	276
5. Miscellaneous Cyclizations	276
IV. Metal-Biguanide Complexes	277
1. Synthesis and Structure	277
2. Pharmacological Activity of Complexes	279
3. Use of Biguanide Complexes in Analytical Procedures	280
C. Structure-Activity Relationships	280
References	282

CHAPTER 11

**Physicochemical Properties and Analytical Methods
of Determination of Biguanides**

E. PRUGNARD and M. NOEL. With 3 Figures	287
A. Physical Properties	287
I. General Properties	287
II. Dissociation Constants	287
III. Spectroscopic Data	290
1. Ultraviolet Spectra	290
2. Infrared Spectra	291
3. Nuclear Magnetic Resonance Spectra	292
IV. Crystal Structures and Protonation Sites	292
1. Phenformin	292
2. Metformin	292
B. Quantitative Determination in Biological Medium	296
I. Detection of Antidiabetic Biguanides by Spectrophotometry	296
II. From Micrograms to Nanograms: The Chromatographic Revolution	296
1. Gas Chromatography	296
2. High-Performance Liquid Chromatography	298
3. Miscellaneous	300
References	302

CHAPTER 12

Preclinical Pharmacology of Biguanides

N.F. WIERNSPERGER. With 13 Figures	305
A. Introduction	305
B. Absorption and Distribution	306
I. Absorption	306
II. Tissue Distribution	306
C. Efficacy	308
D. General Pharmacology	309
I. Blood Pressure	309
II. Varia	309
III. Hormones	310
IV. Antitumoral Properties	310
V. Vasculoprotective Effects	310
1. Macrocirculation	310
2. Microcirculation	312
3. Hypertension	313

E. Organ Pharmacology	314
I. Gastrointestinal Tract	314
1. In Vitro	314
2. In Vivo	316
II. Pancreatic Hormone Secretion	318
1. In Vitro	318
2. In Vivo	319
III. Liver	319
1. In Vitro	319
2. In Vivo	321
IV. Adipose Tissue	323
1. In Vitro	323
2. In Vivo	323
V. Skeletal Muscle/Heart	324
1. In Vitro	324
2. In Vivo	324
VI. Other Tissues	327
1. Blood Cells	327
2. Varia	327
F. Lipid Metabolism	328
I. Lipogenesis	328
II. Lipolysis	328
III. Fatty Acids	328
IV. Triglycerides	329
V. Lipoproteins	329
VI. Cholesterol	329
G. Cellular Effects	330
I. Need for Insulin?	330
II. Potentiation of Insulin Actions	330
III. Mechanisms of Insulin Potentiation	332
1. Plasma Insulin	333
2. Insulin Receptor Binding/Phosphorylation	333
3. Postreceptor Mechanisms	334
4. Mechanisms Not Linked with Potentiation	334
5. Insulin-Independent Effects	336
IV. Biguanides: Membrane-Active Drugs	336
1. Supporting Arguments	337
2. Membrane Binding/Cellular Uptake	337
V. Intracellular Effects	341
VI. Conclusions	342
H. Conclusions	343
References	344

CHAPTER 13

Toxicology of Biguanides

F. SCHMIDT, F. HARTIG, W. REBEL, and P. OCHLICH. With 3 Figures ..	359
A. Introduction	359
B. General Pharmacology and Toxicology	359
C. Acute and Chronic Toxicity	360
I. Phenethylbiguanide (Phenformin)	360
1. Biochemical Deviations in Blood Serum and Liver Mitochondria	360
2. Serum Levels and Organ Distribution (Kidneys, Duodenum, Liver and Organelles)	363
3. Acute Toxicity	365
4. Chronic Toxicity	366
II. Butylbiguanide (Buformin)	367
1. Acute Toxicity	367
2. Chronic Toxicity	367
III. Dimethylbiguanide (Metformin)	367
1. Acute Toxicity	367
2. Subchronic and Chronic Toxicity	368
3. Mutagenicity, Fertility and Teratogenicity	369
4. Carcinogenicity Studies	369
D. Comparative Evaluations and Critical Remarks	370
References	370

CHAPTER 14

Clinical Pharmacology of Biguanides

L.S. HERMANN. With 1 Figure	373
A. Introduction	373
B. Pharmacodynamics	374
I. Antihyperglycaemic Effect	374
II. Weight-Stabilizing Effect	377
III. Lipid-Lowering Effect	378
1. Triglycerides, Cholesterol and Lipoproteins	378
2. Free Fatty Acids and Glycerol	380
IV. Insulin-Sensitizing Effect	381
1. Insulin Secretion	381
2. Insulin Levels	382
3. Insulin Action and Insulin Resistance	383
V. Vascular Effects	388
1. Blood Pressure and Renal Effects	388
2. Fibrinolysis, Haemorrheology and Thrombosis	388
VI. Gastrointestinal Effects	390

C. Effects on Metabolic Pathways in Human Diabetes	391
I. Glucose Metabolism	391
II. Lactate Metabolism	393
III. Lipid Metabolism	394
D. Indications	395
E. Contraindications and Precautions	395
F. Combination Therapy	396
I. Metformin Plus Sulphonylurea	396
II. Metformin Plus Insulin	397
G. Pharmacokinetics	397
H. Safety and Tolerance	398
I. Lactic Acidosis	398
II. Gastrointestinal and Other Adverse Effects	399
I. Interactions	400
References	400

Section III: Glucosidase Inhibitors

CHAPTER 15

Chemistry and Structure-Activity Relationships of Glucosidase Inhibitors

B. JUNGE, M. MATZKE, and J. STOLTEFUSS. With 63 Figures	411
A. Introduction	411
B. Pseudoglucosylamines	412
I. Validamine, Valienamine, and Valiolamine	412
II. N-Substituted Valiolamine Derivatives	417
III. Acarviosin Derivatives	419
IV. Acarbose	421
V. Higher Pseudo-oligosaccharides	426
C. Polyhydroxypiperidines and Polyhydroxypyrrolidines	427
I. Nojirimycin	427
II. 1-Deoxynojirimycin	429
III. N-Substituted Derivatives of 1-Deoxynojirimycin	432
IV. Branched and Chain-Extended Deoxynojirimycin Derivatives	444
1. Derivatives Branched at C-1	444
2. Derivatives Branched at C-5	446
3. Derivatives Chain-Extended at C-6	449
V. Deoxy, Amino, and Halogen Derivatives	450
VI. Polyhydroxypiperidines with Altered Configuration	453
VII. Bicyclic Derivatives of Deoxynojirimycin	454

1. Castanospermine	454
2. Castanospermine Derivatives	457
VIII. Polyhydroxypyrrolidines	460
1. Monocyclic Pyrrolidine Derivatives	460
2. Bicyclic Pyrrolidine Derivatives	465
References	467

CHAPTER 16

Analytical Methods of Determination of Glucosidase Inhibitors

H.J. PLOSCHKE, H. SCHLECKER, S. SEIP, and C. WÜNSCHE.

With 5 Figures	483
A. Chromatographic Techniques	483
I. Analytical Methods	483
II. Preparative Methods	484
1. Reverse-Phase Chromatography	485
2. Ion-Exchange Chromatography	487
3. Size-Exclusion Chromatography	487
4. Adsorption Chromatography	488
5. Craig Distribution	488
6. Detection	490
B. Spectroscopic Techniques	490
I. Nuclear Magnetic Resonance	490
II. Mass Spectrometry	492
References	494

CHAPTER 17

Pharmacology of Glucosidase Inhibitors

W. PULS. With 3 Figures	497
A. Introduction	497
B. Intestinal Digestion of Dietary Di-, Oligo- and Polysaccharides by α -Glucosidases	497
C. Exploratory Investigations on the Feasibility of α -Glucosidase Inhibition	498
D. Primary Effects of Glucosidase Inhibitors	500
E. Secondary Effects of Glucosidase Inhibitors	501
I. Investigations to Evaluate the Potency of Glucosidase Inhibitors	501
II. Blood Glucose and Plasma Insulin	503
1. Single-Dose Studies	503
2. Repeated Administration	505

III. Lipid Metabolism	508
1. Blood Lipids	508
2. Tissue Lipids	509
IV. Protein Metabolism	511
V. Hormones	512
1. Pancreatic Insulin	512
2. Catecholamines and Thyroid Hormones	513
3. Other Hormones	513
VI. Vitamins and Trace Metals	514
VII. Exocrine Pancreas	514
VIII. Small and Large Bowel	515
1. Weight, Length and Microflora	515
2. Enzyme Activity Alterations in the Small Intestine	517
3. Enterohormones in the Intestinal Gut Wall	518
IX. Liver	519
1. Glycogen	519
2. Lipids	520
X. Heart	522
XI. Skeletal Muscle	522
XII. Dangerous Late Complications	523
1. Nephropathy	523
2. Neuropathy	524
3. Retinal Microangiopathy	525
References	525

CHAPTER 18

General Pharmacology of Glucosidase Inhibitors

W. PULS	535
A. Introduction	535
B. Neuropharmacological Studies	535
C. Cardiovascular/Respiratory Studies	536
D. Gastrointestinal Function Studies	536
E. Haematological Studies	537
F. Antigenic, Antiallergic and Pulmonary Activity	537
G. Antibacterial, Antimycotic and Antiparasitic Activity	537
H. Other Studies	537
References	538

CHAPTER 19

Pharmacokinetics and Metabolism of Glucosidase Inhibitors

H.P. KRAUSE and H.J. AHR. With 4 Figures	541
A. Introduction	541
B. Acarviosin Derivatives	541
I. Acarbose	541
1. Introduction	541
2. Determination Methods	542
3. Absorption	542
4. Plasma Concentrations	543
5. Protein Binding	543
6. Distribution	543
7. Metabolism	544
8. Excretion	544
C. Valiolamine Derivatives	545
I. AO-128	545
1. Introduction	545
2. Determination Methods	545
3. Absorption	546
4. Plasma Concentrations of Total Radioactivity	546
5. Plasma Concentrations of Unchanged AO-128	546
6. Distribution	546
7. Metabolism	547
8. Excretion	547
D. Deoxynojirimycin Derivatives	547
I. Miglitol	547
1. Introduction	547
2. Determination Methods	548
3. Absorption	548
4. Plasma Concentrations	548
5. Protein Binding	548
6. Distribution	549
7. Metabolism	549
8. Excretion	549
II. Emiglitate	549
1. Introduction	549
2. Absorption	550
3. Plasma Concentrations	550
4. Distribution	550
5. Metabolism	550
6. Excretion	551
III. Other Deoxynojirimycin Derivatives	551
1. 1-Deoxymannojirimycin	551
2. <i>N</i> -methyl-1-deoxynojirimycin	552

E. Comparative Discussion	552
References	554

CHAPTER 20

Toxicology of Glucosidase Inhibitors

E.M. BOMHARD. With 2 Figures	557
A. Acarbose	557
I. General Toxicology	557
1. Acute Toxicity	557
2. Subacute Intravenous Toxicity	557
3. Subchronic Oral Toxicity	558
4. Chronic Toxicity	559
II. Reproduction Toxicology	560
1. Fertility and General Reproductive Performance in Rats	560
2. Embryotoxicity/Teratogenicity in Rats	560
3. Peri-/Postnatal Study in Rats	560
4. Embryotoxicity/Teratogenicity in Rabbits	561
III. Genotoxicity/Mutagenicity	561
IV. Carcinogenicity	561
1. Rat	561
2. Hamster	569
3. Low-Carbohydrate/Emiglitate Lifetime Carcinogenicity Study in Sprague-Dawley Rats	571
V. Toxicokinetics	571
VI. Special Studies	573
1. Glycogen Storage in Rats	573
2. Cell Proliferation in Kidney Cortex	574
3. Electron Microscopic Investigations	575
4. Investigations of Effects on Endocrinium	575
5. Interaction with Other Oral Antidiabetics	575
VII. Assessment of the Carcinogenic Potential of Acarbose	576
1. Significance of Leydig Cell Tumours	576
2. Significance of Epithelial Kidney Tumours in Sprague-Dawley Rats	577
B. Emiglitate	579
I. General Toxicology	579
1. Acute Toxicity	579
2. Subacute Toxicity	580
3. Subchronic Toxicity	580
4. Chronic Toxicity	581
II. Reproduction Toxicology	582

1. Fertility and General Reproductive Performance in Rats	582
2. Embryotoxicity/Teratogenicity in Rats	582
3. Embryotoxicity/Teratogenicity in Rabbits	582
III. Genotoxicity/Mutagenicity	582
IV. Carcinogenicity	582
1. Rat	582
2. Mouse	584
V. Toxicokinetics	584
VI. Special Studies	584
C. Miglitol	585
I. General Toxicology	585
1. Acute Toxicity	585
2. Subacute Toxicity	585
3. Subchronic Toxicity	586
4. Chronic Toxicity	586
II. Reproduction Toxicology	587
1. Fertility and General Reproductive Performance in Rats	587
2. Embryotoxicity/Teratogenicity in Rats	587
3. Peri-/Postnatal Study in Rats	587
4. Embryotoxicity/Teratogenicity in Rabbits	587
III. Genotoxicity/Mutagenicity	588
IV. Carcinogenicity	588
1. Rat	588
2. Mouse	588
V. Toxicokinetics	588
VI. Special Studies	591
D. Voglibose	592
I. General Toxicology	592
1. Acute Toxicity	592
2. Subacute Toxicity	592
3. Subchronic Toxicity	593
4. Chronic Toxicity	595
II. Reproduction Toxicology	596
1. Fertility and General Reproductive Performance in Rats	596
2. Embryotoxicity/Teratogenicity in Rats	596
3. Peri-/Postnatal Study in Rats	597
4. Embryotoxicity/Teratogenicity in Rabbits	598
5. Peri-/Postnatal Study in Rats Fed on a Glucose Diet	598
III. Genotoxicity/Mutagenicity	599
IV. Carcinogenicity	599
1. Rat	599
2. Mouse	600

V. Toxicokinetics	601
VI. Special Studies	601
1. Antigenicity in Guinea Pigs and Mice	601
2. Effect of Dietary Carbohydrates on the Oral Toxicity in Rats	601
3. Effect of Low-Protein Diet on Plasma Transaminases in Rats	602
E. Castanospermine	602
I. General Toxicology	602
1. Acute/Subacute Toxicity	602
II. Reproduction Toxicology	603
III. Genotoxicity/Mutagenicity	603
IV. Carcinogenicity	603
V. Toxicokinetics	603
VI. Special Studies	603
F. Common Toxicological Characteristics of Glucosidase Inhibitors	604
I. Reduced Glucose Utilization	605
II. Lysosomal Glycogen Storage	606
III. Accumulation of Undigested Carbohydrates in the Large Intestine	607
References	608

CHAPTER 21

Clinical Pharmacology of Glucosidase Inhibitors

E. BRENDL and W. WINGENDER. With 4 Figures	611
A. Acarbose	611
I. Introduction	611
II. Pharmacodynamics	611
1. Effects on Blood Sugar and Insulin	611
2. Effects on Gastrointestinal Hormones and Exocrine Pancreatic Function	613
3. Effects on Lipids and Lipoproteins	614
III. Pharmacokinetics	614
IV. Safety and Tolerability	616
V. Interactions	617
B. Deoxynojirimycin Derivatives (Miglitol, Emiglitate)	618
I. Introduction	618
II. Pharmacodynamics	619
1. Effect on Blood Sugar and Insulin	619
2. Effects on Gastrointestinal Hormones	623
3. Effects on Lipids	623
III. Pharmacokinetics	624
IV. Safety and Tolerability	625

V. Interactions	626
C. Other Glucosidase Inhibitors	626
I. Introduction	626
II. Pharmacodynamics	626
References	628

CHAPTER 22

Clinical Evaluation of Glucosidase Inhibitors

R.H. TAYLOR and E.M. BARDOLPH	633
A. Introduction	633
I. Carbohydrate Digestion	633
II. Diet and Glucosidase Inhibitors	634
III. Role of Glucosidase Inhibitors in Diabetes	635
B. Acarbose	635
I. Studies in Type I Diabetes	636
II. Studies in Type II Diabetes	637
1. Clinical Trials	637
2. Effect on Lipids	638
3. Studies Comparing Effects with Other Antidiabetic Agents	639
III. Other Clinical Studies	641
C. Deoxynojirimycin Derivatives	641
I. Studies in Type I Diabetes	642
II. Studies in Type II Diabetes	643
D. Other Glucosidase Inhibitors	644
E. Conclusions	645
References	646

CHAPTER 23

Oral Antidiabetic Drugs in Research and Development

H. BISCHOFF and H.E. LEBOVITZ. With 11 Figures	651
A. Introduction	651
B. Stimulation and Modulation of Insulin Secretion	652
I. Depolarization of the B-Cell Membrane	653
1. Inhibitors of the ATP-Sensitive K ⁺ Channel	653
a) Sulfonylurea Derivatives	653
b) Benzoic Acid Derivatives	655
c) Guanidine Derivatives	656
d) 2-Substituted Imidazoline Derivatives	657
2. Compounds with Uncertain Sites of Action	659
II. α_2 -Adrenoceptor Antagonism	661
III. Ca ²⁺ Channel Modulation	662

C. Suppression of Hepatic Glucose Production	663
I. Inhibition of Fatty Acid Oxidation	664
1. Inhibitors of Carnitine Acylcarnitine Translocase:	
Hydrazonopropionic Acid Derivatives	664
a) Pharmacological Properties	665
b) Effect on Gluconeogenesis and Mode of Action ...	666
c) Clinical Studies	668
2. Inhibitors of Carnitine Palmitoyltransferase I	668
a) Pharmacology and Effects on Gluconeogenesis ...	668
α) 2-Oxirane Carboxylic Acid Derivatives	668
β) Dioxolane Derivative	670
γ) β -Aminobetaine Structures	670
b) Pharmacokinetics and Toxicology	671
c) Clinical Studies	672
D. Enhancement of Insulin Action	673
E. Mimicking of Insulin Action	678
F. Prevention of Deleterious Effects Caused by Glucose	680
I. Aldose Reductase Inhibitors	681
II. Aminoguanidine: An Inhibitor of Advanced Glycation	
End Product Formation	684
References	685

CHAPTER 24

New Approaches for the Treatment of Diabetes Mellitus

J.M. AMATRUDA and M.L. MCCALED	697
A. Prevention	697
I. Non-Insulin-Dependent Diabetes Mellitus	697
II. Insulin-Dependent Diabetes Mellitus	698
B. Obesity	700
I. Central Mechanisms	701
II. Peripheral Mechanisms	703
1. Increased Energy Expenditure	703
2. Decreased Fat Absorption	704
C. Insulin Sensitizers	704
I. Rationale	704
II. Specific Targets	705
III. Amylin and Amylin Blockers	706
D. Alternative Insulin Delivery	707
E. Gene Therapy	709
References	710
Subject Index	715